Overview

ADjuVant Apatinib in Nasopharyngeal Carcinoma Patients With Residual Epstein-Barr Virus (EBV) DNA Following Radiotherapy

Status:
Unknown status

Trial end date:
2021-06-01

Target enrollment:

Participant gender:

Summary

This study will enroll patients with non-metastatic nasopharyngeal carcinoma (NPC) that have residual Epstein-Barr virus (EBV) DNA after curative radiotherapy or chemoradiotherapy. The purpose is to evaluate the survival in these patients treated with apatinib (YN968D1), an inhibitor of vascular endothelial growth factor receptor (phase IIa) and to compare the survival in these patients treated with apatinib versus placebo (phase IIb).

Phase:

Phase 2

Details

Lead Sponsor:

Sun Yat-sen University

Collaborators:

First People's Hospital of Foshan
Guilin Medical University, China

Treatments:

Apatinib